What it is
Oritavancin is an antibiotic of the lipoglycopeptide class — vancomycin's peptide core, rebuilt. The Orbactiv label calls it "a semisynthetic lipoglycopeptide antibacterial drug," and its chemical name is written as vancomycin with two additions: an extra amino sugar (3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl) and a (4'-chloro-biphenyl-4-yl)methyl group on another sugar. That fat-loving biphenyl arm is the "lipo" in its class name.
| Property | Value | Source |
|---|---|---|
| Formula (free) | C86H97Cl3N10O26 | PubChem CID 16136912 |
| Molecular weight | 1,793.1 (free) · 1,989.09 (diphosphate salt) | PubChem · label |
| Orbactiv vial | 400 mg oritavancin (three make the 1,200 mg dose) | label |
| Kimyrsa vial | 1,200 mg oritavancin, with hydroxypropyl-β-cyclodextrin | label |
The library's glycopeptide antibiotics entry places it with vancomycin, dalbavancin, the once-daily lipoglycopeptide telavancin and teicoplanin.
How it works
The label section on mechanism says only that oritavancin "is an antibacterial drug" and points to its microbiology section; this entry does not go beyond that. What the label does quantify is how it behaves in the body: about 85% protein-bound, a population volume of distribution of about 87.6 L ("extensively distributed into the tissues"), no metabolism seen in human liver microsome studies, linear kinetics up to 1,200 mg and a multi-exponential decline with a long terminal half-life. After one 1,200 mg dose in 297 trial patients, mean peak concentration was 138 µg/mL and total exposure (AUC 0–∞) 2,800 µg·h/mL.
That long tail is what allows one infusion to replace a week or more of treatment.
What the evidence shows
The approval rests on two identically designed, double-blind, non-inferiority trials — SOLO I and SOLO II — in 1,987 adults with cellulitis or erysipelas (40%), wound infections (29%) or major abscesses (31%). One 1,200 mg dose of oritavancin was compared with intravenous vancomycin every 12 hours for 7 to 10 days.
| End point (48–72 h) | Trial | Oritavancin | Vancomycin | Difference (95% CI) |
|---|---|---|---|---|
| Early clinical response | 1 | 391/475 (82.3%) | 378/479 (78.9%) | 3.4 (−1.6 to 8.4) |
| Early clinical response | 2 | 403/503 (80.1%) | 416/502 (82.9%) | −2.7 (−7.5 to 2.0) |
| Lesion shrunk ≥20% | 1 | 86.9% | 82.9% | 4.1 (−0.5 to 8.6) |
| Lesion shrunk ≥20% | 2 | 85.9% | 85.3% | 0.6 (−3.7 to 5.0) |
The SOLO I paper (NEJM 2014, PMID 24897083; funded by The Medicines Company) concluded that a single dose was non-inferior to the vancomycin course. Non-inferior means "not meaningfully worse within a set margin," not "better."
Kimyrsa, the second product, was approved on the basis of those trials plus a study of the faster infusion: 50 patients on each schedule reached almost identical exposure (AUC 0–72 of 1,460 and 1,470 µg·h/mL), with a higher peak on the 1-hour infusion (148 v 112 µg/mL).
The warning that surprises people is about blood tests, not bleeding. Oritavancin falsely prolongs the aPTT for up to 120 hours, PT and INR for up to 12 hours and ACT for up to 24 hours, so a patient on heparin may need a different test; with warfarin, the label calls for monitoring for bleeding. Other warnings: hypersensitivity (with care in people allergic to other glycopeptides), infusion reactions, C. difficile diarrhoea, and osteomyelitis needing alternative treatment. The common reactions (3% or more) were headache, nausea, vomiting, limb and skin abscesses, and diarrhoea.
What is not established on the label: use in children (a 118-child safety study is listed as completed on ClinicalTrials.gov), or for infections of implanted heart devices, which one registered study (NCT07013552) plans to test.
Where it stands
Two US products, both Melinta Therapeutics: Orbactiv (NDA 206334, approved 6 August 2014) and Kimyrsa (NDA 214155, approved 12 March 2021). Both are indicated only for acute bacterial skin and skin-structure infections in adults caused by susceptible Gram-positive bacteria, including MRSA and vancomycin-susceptible Enterococcus faecalis.
Sources opened 2026-11-18: Orbactiv label (openFDA, effective 2026-09-15: sections 1, 2, 5, 6, 11, 12.3, 14); Kimyrsa label (effective 2025-12-18: sections 2, 6, 11, 12.3); Drugs@FDA NDA 206334 and NDA 214155; PubChem CID 16136912; SOLO I, NEJM 2014 (PMID 24897083, abstract); ClinicalTrials.gov API v2 (21 records); PubMed E-utilities counts.
